CLOVIS ONCOLOGY, INC.

(CLVS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/12/2022 05/13/2022 05/16/2022 05/17/2022 05/18/2022 Date
0.761(c) 0.7815(c) 0.8292(c) 0.7814(c) 0.7401(c) Last
5 630 156 3 824 751 4 577 296 5 779 555 3 843 944 Volume
+1.64% +2.69% +6.10% -5.76% -5.29% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 155 M - -
Net income 2022 -229 M - -
Net Debt 2022 312 M - -
P/E ratio 2022 -0,43x
Yield 2022 -
Sales 2023 211 M - -
Net income 2023 -174 M - -
Net Debt 2023 326 M - -
P/E ratio 2023 -0,79x
Yield 2023 -
Capitalization 106 M 106 M -
EV / Sales 2022 2,70x
EV / Sales 2023 2,05x
Nbr of Employees 413
Free-Float 98,6%
More Financials
Company
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent... 
More about the company
Ratings of Clovis Oncology, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about CLOVIS ONCOLOGY, INC.
05/11TRANSCRIPT : Clovis Oncology, Inc. Presents at Bank of America 2022 Healthcare Conference,..
CI
05/05CLOVIS ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
05/05Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
BU
05/04TRANSCRIPT : Clovis Oncology, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on C..
BU
05/04CLOVIS : Q1 Earnings Snapshot
AQ
05/04Earnings Flash (CLVS) CLOVIS ONCOLOGY Reports Q1 Loss $-0.44, vs. Street Est of $-0.49
MT
05/04Clovis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
04/28Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 20..
BU
04/20Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Confe..
BU
04/08Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AA..
BU
04/08Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® at the AACR Annual Me..
CI
03/31SECTOR UPDATE : Health Care Stocks Sidestep Steeper Thursday Market Losses
MT
03/31SECTOR UPDATE : Health Care Stocks Mixed in Thursday Trading
MT
03/31SECTOR UPDATE : Health Care
MT
More news
News in other languages on CLOVIS ONCOLOGY, INC.
05/04Clovis Oncology, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2..
04/08Clovis Oncology souligne les présentations sur le FAP-2286 et le Rubraca® (Rucaparib) l..
03/31MISE À JOUR SECTORIELLE : Les actions du secteur de la santé évitent des pertes de marché ..
03/31Clovis Oncology déclare que le traitement du cancer ovarien a atteint le critère princi..
03/31La Bourse s'apprête à ouvrir à plat ; les inscriptions au chômage sont plus élevées que..
More news
Analyst Recommendations on CLOVIS ONCOLOGY, INC.
More recommendations
Chart CLOVIS ONCOLOGY, INC.
Duration : Period :
Clovis Oncology, Inc. Technical Analysis Chart | CLVS | US1894641000 | MarketScreener
Technical analysis trends CLOVIS ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 0,74 $
Average target price 2,25 $
Spread / Average Target 204%
EPS Revisions
Managers and Directors
Patrick J. Mahaffy President, Chief Executive Officer & Director
Daniel W. Muehl Principal Accounting Officer & Senior VP-Finance
Ginger L. Graham Chairman
Lindsey Rolfe Senior Vice President-Clinical Development
Thomas Fuglsang Harding Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
CLOVIS ONCOLOGY, INC.-72.69%106
GILEAD SCIENCES, INC.-12.93%79 298
REGENERON PHARMACEUTICALS, INC.4.38%71 026
VERTEX PHARMACEUTICALS14.91%64 540
WUXI APPTEC CO., LTD.-18.77%41 409
BIONTECH SE-39.08%38 169